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Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide.
Current therapies are insufficient, making HCC an intractable disease. Our previous studies confirmed that inhibition
of protein phosphatase 2A (PP2A) may provide a promising therapeutic strategy for cancer. Unfortunately,
constitutive expression of PP2A in normal tissues limits the application of PP2A inhibition. Thus, a HCC-specific gene
delivery system should be developed. The α-fetoprotein (AFP) promoter is commonly used in HCC-specific gene
therapy strategies; however, the utility of this approach is limited due to the weak activity of the AFP promoter. It
has been shown that linking the AFP enhancer with the promoter of the non-tissue-specific, human housekeeping
phosphoglycerate kinase (pgk) gene can generate a strong and HCC-selective promoter.
Methods: We constructed a HCC-specific gene therapy system to target PP2A using the AFP enhancer/pgk
promoter, and evaluated the efficiency and specificity of this system both in vitro and in vivo.
Results: AFP enhancer/pgk promoter-driven expression of the dominant negative form of the PP2A catalytic
subunit α (DN-PP2Acα) exerted cytotoxic effects against an AFP-positive human hepatoma cell lines (HepG2 and
Hep3B), but did not affect AFP-negative human hepatoma cells (SK-HEP-1) or normal human liver cells (L-02).
Moreover, AFP enhancer/pgk promoter driven expression of DN-PP2Acα inhibited the growth of AFP-positive
HepG2 tumors in nude mice bearing solid tumor xenografts, but did not affect AFP-negative SK-HEP-1 tumors.
Conclusions: The novel approach of AFP enhancer/pgk promoter-driven expression of DN-PP2Acα may provide a
useful cancer gene therapy strategy to selectively target HCC.
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Hepatocellular carcinoma (HCC) is one of the most
prevalent tumor types worldwide, especially in several
areas of Asia and Africa [1,2]. HCC leads to approximately
662,000 deaths worldwide every year, and the mortality
rate is increasing [3,4]. In spite of improvements in
diagnosis and clinical treatment methods, HCC remains
an aggressive malignant tumor due to the nonspecific
symptoms, invasiveness, resistance to chemotherapy and
high rate of tumor recurrence [3]. HCC is closely asso-
ciated with chronic liver disease, particularly cirrhosis
due to hepatitis B virus or hepatitis C virus infection
[1,5]. Patients with liver cirrhosis and HCC are often
poor candidates for surgery, even if the HCC is detected
at an early stage, as they generally lack a hepatic reserve
as a result of the coexisting advanced cirrhosis [1].
Therefore, new treatments against this aggressive neo-
plasm are urgently needed.
Cantharidin, the active constituent of the mylabris
Chinese blister beetle, has been used as a traditional
Chinese medicine for more than 2000 years and is still
used as a folk medicine. Cantharidin has an affinity for
the liver [6], and has demonstrated therapeutic effects
against HCC in clinical trials without suppressing bone
marrow function, even in patients at an advanced stage
[6,7]. Cantharidin is a potent and selective inhibitor of
protein phosphatase 2A (PP2A). The core enzyme of
PP2A consists of a catalytic subunit (PP2Ac) and a regu-
latory A subunit (PP2Aa). A third regulatory B subunit
can be associated with this core structure, and this
modulates the substrate specificity of PP2A. At present,
two isoforms of the α and β catalytic subunits have
been identified [8,9]. In previous studies, we proved
that cantharidin repressed cancer cell proliferation and
triggered apoptosis in a mechanism dependent on the
inhibition of PP2A, suggesting that PP2A inhibition
may provide a novel approach for hepatoma therapy
[7,10,11]. However, the cytotoxicity of cantharidin in
normal hepatic tissue and the urinary system restricts
its clinical application [6], indicating that a cancer
tissue-specific therapy strategy should be developed for
the inhibition of PP2A.
Gene therapy using tumor- or tissue-specific promoter-
driven suicide genes, immunosuppressors, antiangiogenic
genes or tumor suppressor genes is a promising approach
for the treatment of cancer. Expression of the α-fetopro-
tein (AFP) gene is reactivated in HCC cells; however, the
therapeutic results of AFP promoter-driven gene therapy
are unsatisfactory, as the transcriptional activity of this
promoter is usually weak. It has been proven that the
enhancer and silencer regions located upstream of the
AFP gene play a critical role in the selective expression of
AFP in HCC. Additionally, the AFP enhancer fragment
may provide HCC-specific activity to the promoter of thenon-tissue-specific, housekeeping phosphoglycerate kinase
(pgk) gene, and this novel strategy may be useful for HCC-
specific cancer gene therapy [12].
Therefore, in the present study, we attempted to de-
velop a HCC-specific gene therapy system by expressing
a dominant negative mutant form of the PP2A catalytic
subunit α (DN-PP2Acα) [13] under direct transcriptional
control of the AFP enhancer/pgk promoter, and investi-
gated the therapeutic effects of this system in HCC
in vitro and in vivo.
Methods
Cell lines and culture
The AFP-positive human hepatoma cell lines, HepG2 and
Hep3B, the AFP-negative human hepatoma cell line SK-
HEP-1, and the normal human liver cell line L-02 were
purchased from the American Type Culture Collection
(Manassas, VA, USA). The cells were maintained in RPMI-
1640 medium (DMEM; Gibco, Grand Island, NY, USA)
supplemented with 10% fetal calf serum (FCS; Hyclone,
Logan, UT, USA), 100 U/ml penicillin and 100 mg/ml
streptomycin. The cultures were incubated at 37°C in a hu-
midified atmosphere containing 5% CO2, and passaged
every 2–3 days to maintain exponential growth.
MTT assay
Cellular growth was evaluated using the 3-[4,5-dimethyl-
tiazol-2-yl] 2,5-diphenyl-tetrazolium bromide (MTT)
assay [14]. The cells were seeded in 96-well plates at
5×103 cells/well. After treatment, MTT (Sigma, St. Louis,
MO, USA) was added to each well at a final concentration
of 0.5 mg/ml and incubated at 37°C for 4 h. The media
was removed, 200 μl dimethyl sulphoxide (DMSO) was
added to each well and the absorbance was measured at
490 nm using a microplate ELISA reader (Bio-Rad
Laboratories, Hercules, CA, USA). The inhibition rate was
calculated as follows: inhibition rate = [(mean control
absorbance-mean experimental absorbance)/mean control
absorbance] × 100 (%). The concentration which caused a
50% growth inhibition (IC50) was calculated using the
modified Kärbers method [15] according to the formula:
IC50 = lg
− 1[Xk − i(
P
p − 0.5)], where Xk represents the
logarithm of the highest drug concentration; i is the ratio
of the adjacent concentration; and ΣP is the sum of the
percentage growth inhibition at various concentrations.
The relative cell viability was calculated as follows: relative
cell viability = (mean experimental absorbance/mean
control absorbance) × 100 (%).
Serine/threonine phosphatase assay
PP2A activity was analyzed using the nonradioactive
serine/threonine-phosphatase assay kit (Promega, Madison,
WI, USA) according to the manufacturer’s protocol. In
brief, the cell lysate supernatant was passed twice through
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the eluate was placed into 96-well plates, and the assay was
performed in the presence of a PP2A-specific serine/threo-
nine phosphopeptide substrate (RRApTVA, in which pT
represents phosphothreonine). Molybdate dye solution
was added to the wells, incubated for 30 min at room
temperature, color development was observed, absorbance
was measured at 630 nm, and the amount of phosphate
released was calculated using a standard curve. The relative
activity of PP2A was calculated according to the following
equation: PP2A activity = (mean experimental phosphate
amount/mean control phosphate amount) × 100 (%).Site-directed mutagenesis
Wild-type PP2A catalytic subunit α (PP2Acα) was
cloned as previously described [10]. The dominant
negative mutant form of PP2Acα (DN-PP2Acα) was
PCR-amplified from wild-type PP2Acα (WT-PP2Acα)
using site-directed mutagenesis to mutate Leu 199 to
Pro [13]. Site-directed mutagenesis was performed by
primed PCR amplification of the plasmid [16]. Plasmid
template DNA (10 ng) was added to a PCR cocktail
containing PrimerSTAR HS DNA polymerase (TAKARA
Biochemicals, Dalian, China) and the mutagenic oligo-
nucleotide primers: sense: 5’-CCAATGTGTGACTTGCCG
TGGTCAGATCCAGATG-3’; anti-sense: 5’-CATCTGGA
TCTGACCACGGCAAGTCACACATTGG-3’. The PCR
cycling parameters were 30 s at 95°C, followed by 18
cycles of 30 s at 95°C, 1 min at 55°C and 10 min at 72°C.
The reaction was placed on ice for 2 minutes, 1 μl Dpn I
(10 U/μl, New England Biolabs, Ipswich, Massachusetts,
USA) was added, incubated at 37°C overnight to digest
the parental (i.e., the non-mutated) plasmid template
DNA [17] and the recircularized vector DNA incorpo-
rating the desired mutations was transformed into
competent DH5α E. coli.Western blotting
Total protein was extracted using a lysis buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 1 mM EDTA and supplemented with
protease inhibitors [10 mg/ml leupeptin, 10 mg/ml apro-
tinin, 10 mg/mL pepstatin A, and 1 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride]. The protein extract was loaded,
size-fractionated by SDS–polyacrylamide gel electropho-
resis and transferred to PVDF membranes (Bio-Rad La-
boratories, Hercules, CA, USA). After blocking, the mem-
branes were incubated with primary antibodies at 4°C
overnight and protein expression was visualized using horse-
radish peroxidase-conjugated antibodies and enhanced
chemiluminescence (ECL) (Amersham Pharmacia Biotech,
Buckinghamshire, UK). β-actin was used as an internal
control.Luciferase reporter gene assay
The pgk promoter [18] was cloned into pGL3-Basic
(Promega, Madison, WI, USA) using the NheI and BglII
restriction enzymes (New England Biolabs, Beverly, MA,
USA) to generate the reporter plasmid, pGL3-Basic-pgk.
The reporter plasmid, pGL3-Basic-AFpg, containing the
AFP enhancer and pgk promoter was constructed as
previously described [12]. In brief, the AFP enhancer,
including the A and B domains [19], was cloned into
pGL3-Basic using the KpnI and NheI restriction enzymes,
then the pgk promoter [18] was cloned into the NheI and
BglII restriction sites. The positive control reporter plas-
mid, pGL3-Control, which contained the SV40 promoter
and enhancer sequences, and the internal control plasmid,
pRL-SV40, containing the Renilla luciferase gene, were
obtained from Promega. Cells were seeded in 24-well
plates and transiently co-transfected with the reporter
plasmids (500 ng/well) and the pRL-SV40 plasmid (100
ng/well) using X-tremeGENE HP DNA Transfection
Reagent (Roche, Indianapolis, USA) according to the
manufacturer's protocol, and the media was renewed after
8 h. After 24 h, the cells were lysed and luciferase activity
was measured using the Dual-Luciferase Reporter Assay
System (Promega) according to the manufacturer's recom-
mendations using the TD-20/20 luminometer (Turner
Designs, Sunnyvale, CA, USA). The results were expressed
as relative luciferase activity (the ratio of firefly luciferase
activity to Renilla luciferase activity).
Preparation of recombinant adenoviruses
The shuttle plasmids were respectively recombined with
the backbone vector pAdEasy-1 in BJ5183 bacteria.
Adenovirus generation, amplification, and titration were
performed as previously described [20] and viral parti-
cles were purified using the Virabind adenovirus purifi-
cation kit (Cell Biolabs, Inc., San Diego, CA, USA).
Apoptosis and cell cycle distribution analysis
Apoptosis was quantified and the cell cycle was analyzed
as described by Nicoletti et al. [21]. Briefly, the cells were
fixed in 80% chilled ethanol 48 h after treatment, and
then incubated with 0.5% Triton X-100 solution con-
taining 1 mg/ml RNase A at 37°C for 30 min. Propidium
iodide (PI; Sigma) was added at a final concentration of
50 μg/ml, incubated for 30 min in the dark, and the
cellular DNA content was analyzed using a fluorescence-
activated cell sorter (FACS; Becton Dickinson, San Jose,
CA, USA) and the data was processed using WinMDI29
software (Becton Dickinson).
Clone-formation assay
Cells were seeded at a density of 1,000 cells/well in
6-well plates, and treated 12 h later. After 10 days, the
cells were stained with 1% methylrosanilinium chloride
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relative clone formation ability was calculated as: relative
clone formation ability = (mean experimental clone
number/mean control clone number) × 100 (%).
Tumor xenograft model and adenovirus treatment
Six- to eight-week old male BALB/c athymic nude mice
were purchased from the Shanghai Experimental Animal
Center (Shanghai, China) and inoculated on the flank
with 5 × 106 HepG2 or SK-Hep-1 cells. Tumors were
allowed to grow to a volume of 100 mm3, and the ani-
mals were divided into four treatment groups: control
vehicle injection (n = 6); Ad-CMV-DN-PP2Acα injection
(n = 6); Ad-AFpg-luciferase injection (n = 6) and
Ad-AFpg-DN-PP2Acα injection (n = 6). Adenovirus vec-
tors (1 × 108 plaque forming units/100 μl) were injected
directly into the tumor foci center on days 0, 2 and 4 of
treatment. Tumor length and width were measured with
calipers over a period of five weeks. Tumor volume was
calculated as (length × width2)/2. All animals received
humane care according to the Institutional Animal Care
and Treatment Committee of Soochow University.
Statistical analysis
Results were expressed as the mean value ± standard
deviation (S.D.). Statistical analysis was performed using
unpaired Student’s t-tests; P values less than 0.05 were
considered significant.
Results
Inhibition of PP2A represses the growth of HCC cells and
normal human liver cells
The cytotoxic effect of cantharidin against HCC has
been widely explored [22,23]. As shown in Figure 1A,
cantharidin repressed the growth of normal liver cells
and HCC cells in a dose- and time-dependent manner.
The IC50 of cantharidin in L-02, SK-Hep-1, HepG2 and
Hep3B cells at 48 h was 24.97, 15.87, 10.64 and 10.56 μM,
respectively. Although cantharidin showed lower cytotoxic
effects in normal cells than in cancer cells [23], the poten-
tial of cantharidin to harm normal tissues is noteworthy.
In fact, the cytotoxicity of cantharidin in normal tissues,
especially the hepatic tissue and urinary system, limits the
clinical application of cantharidin [6].
Our previous studies confirmed that the mechanism of
tumor suppression by cantharidin is mediated via
inhibition of PP2A [7,10,11], indicating that PP2A could
provide a potential target for the treatment of cancer.
To evaluate the cytotoxic effect of specific inhibition of
PP2A, a vector carrying dominant negative mutant form
of PP2Acα (DN-PP2Acα) was developed. DN-PP2Acα
was generated from wild-type PP2Acα (WT-PP2Acα)
using site-directed mutagenesis (Figure 1B). As shown in
Figure 1C, transfection of pcDNA3.1(+)-DN-PP2Acαrepressed the activity of PP2A and inhibited the cell
viability of normal liver and HCC cells. However, CMV
promoter-driven expression of DN-PP2Acα is not cancer
specific, as the CMV promoter drives target gene ex-
pression in both normal and cancer cells. Therefore, we
designed a tumor specific promoter to achieve HCC-
specific inhibition of PP2A.
AFP-positive-specific expression of DN-PP2Acα using the
AFP enhancer/pgk promoter
It has been demonstrated that linkage of the AFP enhan-
cer region to the promoter of the non-tissue-specific
housekeeping pgk gene may result in increased selecti-
vity for HCC [12]. The luciferase reporter gene assay
was used to evaluate the specificity of the AFP enhan-
cer/pgk promoter (AFpg promoter). The transcriptional
activity of the AFpg promoter was tested in various cell
types, including an AFP-positive human hepatoma cell
lines (HepG2 and Hep3B), an AFP-negative human
hepatoma cell line (SK-Hep-1), and a normal human
liver cell line (L-02). Transient transfection experiments
demonstrated that luciferase activity was observed in all
four cell lines (L-02, SK-Hep-1, HepG2 and Hep3B) with
a similar efficiency when transfected with either pGL3-
Basic-pgk or pGL3-Control. The activity of the AFpg
promoter was much lower than the pgk promoter in
AFP-negative cells (L-02 and SK-Hep-1), but much
higher in AFP-positive HepG2 and Hep3B cells
(Figure 2A), This indicated that the AFP enhancer gave
the specificity to the pgk promoter and the AFpg pro-
moter may be a valuable AFP-positive-specific promoter
for gene therapy targeting HCC.
To generate an DN-PP2Acα expression vector driven
by the AFpg promoter, we replaced the luciferase
sequence of pGL3-Basic-AFpg with the coding sequence
of pcDNA3.1(+)-DN-PP2Acα. The coding sequence of
DN-PP2Acα was PCR-amplified from pcDNA3.1(+)-DN-
PP2Acα, digested using BamHI and NheI, and cloned into
the isocaudamer restriction sites, BglII and XbaI, of pGL3-
Basic-AFpg. (Figure 2B). Then, the CMV-DN-PP2Acα se-
quence of pcDNA3.1(+)-DN-PP2Acα, the AFpg-luciferase
sequence of pGL3-Basic-AFpg and the AFpg-DN-PP2Acα
sequence of pGL3-Basic-AFpg-DN-PP2Acα were cloned
separately into pAdTrack using the EcoRV and SalI re-
striction enzymes to generate the adenovirus (Figure 2C).
To determine the transfer efficiency and specificity of
adenovirus mediated gene expression driven by the
AFpg promoter, cells were transduced with Ad-AFpg-
luciferase at various multiplicity of infection (MOI)
levels. Luciferase activity increased in a dose-dependent
manner in two AFP-positive cell lines (HepG2 and
Hep3B), but not the AFP-negative cells, L-02 and SK-
Hep-1 (Figure 2D).
Figure 1 Inhibition of PP2A induces cytotoxic effects. (A) The MTT assay revealed that the PP2A inhibitor cantharidin repressed cell viability in
a dose- and time-dependent manner. (B) Sequencing of PP2Acα and DN-PP2Acα. DN-PP2Acα was generated from WT-PP2Acα using site-directed
mutagenesis to mutate Leu 199 into Pro. (C) The serine/threonine phosphatase assay and MTT assay showed that overexpression of DN-PP2Acα
repressed the activity of PP2A and reduced cell viability 48 h after transfection; *P < 0.05 and **P < 0.01 compared to the respective control groups.
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lar aspects. As shown in Figure 2E, the expression of PP2Ac
after transduction with Ad-AFpg-luciferase was not signifi-
cantly different to the control vehicle group. Transduction
with Ad-CMV-DN-PP2Acα induced overexpression of
PP2Ac in L-02, SK-Hep-1, HepG2 and Hep3B cells, whereas
infection with Ad-AFpg-DN-PP2Acα only led to the over-
expression of PP2Ac in AFP-positive HepG2 and Hep3Bcells, but not in AFP-negative L-02 or SK-Hep-1 cells. This
data indicated that the AFpg promoter led to the specific
expression of DN-PP2Acα in AFP-positive HCC cells.
Ad-AFpg-DN-PP2Acα selectively triggers apoptosis and
G2/M cell cycle arrest in AFP-positive HCC cells
In our previous studies, we reported that PP2A inhibi-
tors exerted cytotoxic effects in cancer cells by
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G2/M phase [7,10,11]. In this study, we tested the
effect of DN-PP2Acα expression driven by the AFpg
promoter on apoptosis and cell cycle distribution. As
shown in Figure 3, transduction with Ad-CMV-DN-
PP2Acα induced apoptosis and G2/M cell cycle arrest
in L-02, SK-Hep-1, HepG2 and Hep3B cells. Transduc-
tion of Ad-AFpg-luciferase did not significantly alter the
level of apoptosis or cell cycle distribution, compared to
the control vehicle group. Infection of Ad-AFpg-DN-
PP2Acα only triggered apoptosis and G2/M cell cycle ar-
rest in AFP-positive HepG2 and Hep3B cells, but had no
effect in AFP-negative L-02 or SK-Hep-1 cells, indicating
that specific expression of DN-PP2Acα driven by the AFpg
promoter selectively induced apoptosis and cell cycle
arrest in AFP-positive HCC cells.Figure 2 Specific overexpression of DN-PP2Acα using the AFP enhanc
(A) The transcriptional activities of the SV40, pgk and AFpg promoters in L-0
reporter gene assay. (B) Construction of the DN-PP2Acα expression vector
for preparation of recombinant adenoviruses. (D) Adenovirus-mediated gen
various MOI levels. At 24 h post-infection, a luciferase activity assay was pe
infection of cells with recombinant adenoviruses at a MOI of 100.Tissue-specific cytotoxicity of Ad-AFpg-DN-PP2Acα in
AFP-positive HCC cells
The effect of DN-PP2Acα expression driven by the AFpg
promoter on cell growth was further evaluated in vitro
and in vivo. Firstly, in vitro studies were performed using
the MTT assay and clone formation assay. As shown in
Figure 4A, the MTT assay revealed that treatment with
Ad-CMV-DN-PP2Acα repressed cell viability in all four
cell lines in a time- and dose-dependent manner; how-
ever, Ad-AFpg-DN-PP2Acα exerted selective toxicity in
AFP-positive HepG2 and Hep3B cells in a time- and
dose-dependent manner, but not in AFP-negative L-02
or SK-Hep-1 cells. The clone-formation assay revealed
that treatment with Ad-CMV-DN-PP2Acα repressed cell
clone-formation ability in all four cell lines; whereas Ad-
AFpg-DN-PP2Acα repressed the cell clone-formationer/pgk promoter (AFpg promoter) in AFP-positive HCC cells.
2, SK-Hep-1, HepG2 and Hep3B cells were tested using the luciferase
driven by the AFpg promoter. (C) Construction of the shuttle plasmids
e transfer efficiency. Cells were infected with Ad-AFpg-luciferase at
rformed. (E) Western blot analysis of DN-PP2Acα expression after
Figure 3 Expression of DN-PP2Acα driven by the AFpg promoter selectively induces apoptosis and alters the cell cycle distribution in
AFP-positive HCC cells. Cells were transducted with recombinant adenoviruses at a MOI of 100. Flow cytometry analysis was performed at 48 h
post-infection; *P < 0.05 and **P < 0.01 indicate significant differences compared to the control vehicle group.
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AFP-negative L-02 or SK-Hep-1 cells (Figure 4B).
To extend these findings, in vivo studies were performed
using SK-Hep-1 and HepG2 xenograft tumor-bearing
mice. In mice injected with control vehicle or Ad-AFpg-
luciferase, the tumors continued to grow by day 30.
Injection of Ad-CMV-DN-PP2Acα significantly dimi-
nished the size of both SK-Hep-1 and HepG2 xenograft
tumors; however, Ad-AFpg-DN-PP2Acα only inhibited the
growth of HepG2 tumor xenografts (Figure 4C). Taken
together, these data support the hypothesis that AFpg
promoter-driven expression of DN-PP2Acα can induce
specific growth inhibition in AFP-positive HCC cells both
in vitro and in vivo.
Discussion
Gene therapy is a promising approach for the treatment
of cancer, and enables the transfer of genetic material to
cells to produce a therapeutic effect. A successful gene
therapy strategy requires both an effective target gene
and a promoter which exhibits high levels of cancer-
specific expression.PP2A (protein phosphatase 2A) is a multimeric serine/
threonine phosphatase [24]. In our previous studies, we
found that inhibition of PP2A exerted a cytotoxic effect in
cancer cells [7,10,11]. Moreover, cantharidin, a potent
and selective inhibitor of PP2A, demonstrated promising
therapeutic effects against HCC in clinical trials [6,7], sug-
gesting PP2A is a promising target for the treatment of
HCC. Unfortunately, the extensive constitutive expression
of PP2A in normal tissues, and its complex physiological
function obstruct the application of PP2A as a therapeutic
target for the treatment of cancer. In clinical trials,
cantharidin exerted cytotoxic effects against normal
hepatic tissue and the urinary system [6], indicating that
the therapeutic inhibition of PP2A must be mediated
using a cancer tissue-specific gene delivery system.
To develop a gene therapy system targeting PP2A, we
firstly constructed a DN-PP2Acα expression vector
driven by the cytomegalovirus (CMV) promoter. The
CMV promoter has been widely used, as it is one of the
strongest promoters in mammalian cells. The expression
of DN-PP2Acα driven by the CMV promoter induced
cytotoxicity in HCC cells. The mechanism of DN-
Figure 4 Expression of DN-PP2Acα driven by the AFpg promoter selectively induces cytotoxic effects in AFP-positive HCC cells in vitro
and in vivo. (A) Cells were transducted with recombinant adenoviruses at various MOI levels. At 12 h, 24 h, and 48 h post-infection, the MTT
assay was performed. (B) Cells were transducted with recombinant adenoviruses at a MOI of 100. After 10 days, the number of visible colonies
were counted. (C) Effect of AFpg promoter-driven DN-PP2Acα expression on the growth of implanted SK-Hep-1 and HepG2 tumors in athymic
mice. Adenoviral gene therapy was initiated when tumors attained a volume of 100 mm3. Tumor volume was calculated as (length × width2)/2;
*P < 0.05 and **P < 0.01 indicate significant differences compared to the control vehicle group.
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levels of apoptosis and triggering of G2/M cell cycle
arrest, as previously described [7,10,11], suggesting that
PP2A is a promising target for the treatment of HCC.
However, the CMV promoter induces target gene ex-
pression in both normal cells and cancer cells. As CMV
promoter-driven expression of DN-PP2Acα induced
cytotoxicity in both HCC cells and normal liver cells,
cancer-specific delivery and/or gene expression are crit-
ical for the safety of gene therapy approaches which aim
to inhibit PP2A. To solve this problem, one important
approach is to use tumor-specific promoters.
Many cancers often re-express fetal or embryonic genes,
and AFP gene expression is reactivated in HCC cells. Al-
though the AFP promoter is a promising candidate for
achieving selective transgene expression in HCC, the weak
activity of the AFP promoter may limit its utility for gene
therapy strategies targeting HCC. It has been proven that the
AFP enhancer fragment can provide HCC-selective activity to
the promoter of the non-tissue-specific, housekeeping gene
pgk. The pgk promoter is recognized as a general, strong pro-
moter and has been used for various gene transfer experi-
ments [25-27]. In this study, addition of the human AFP
enhancer fragment to the pgk promoter provided selectivity
to the non-tissue-specific pgk promoter in AFP-expressing
HCC cells, as previously described [12]. The AFpg promoter
induced selective cytotoxic effects of DN-PP2Acα in AFP-
positive cells. As the AFpg promoter has not been evaluated
in vivo, we examined the cytotoxic effect of specific exp-
ression of DN-PP2Acα, driven by the AFpg promoter, in
AFP-positive cells using a tumor xenograft model. Ad-AFpg-
DN-PP2Acα restrained the tumor growth of AFP-positive
xenografts in vivo, but did not affect AFP-negative xenografts.
Conclusions
In this study, we developed a hepatocellular carcinoma
(HCC)-specific gene therapy system by expressing a dom-
inant negative mutant form of the PP2A catalytic subunit
under direct transcriptional control of the AFP enhancer/
pgk promoter, and investigated the therapeutic effects of
this system in HCC in vitro and in vivo. The data presented
indicates that the use of a vector construct targeting PP2A,
under the transcriptional control of the AFP enhancer frag-
ment and the pgk promoter, is a practical and promising
strategy to deliver HCC-specific gene therapy.
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